2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ocular Manifestations in Colombian Patients with Systemic Rheumatologic Diseases

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          To establish the prevalence of ocular involvement in a Colombian population with rheumatologic diseases.

          Design

          Observational cross-sectional study.

          Methods

          We included a probabilistic sample size of 797 patients who attended a rheumatologic disease center in Bogotá, Colombia. Statistical analysis with descriptive measures and Chi-square independence test between rheumatologic diseases and ophthalmological symptoms and diseases was performed.

          Results

          Eighty-four percent of the population were women, and the mean age was 54.61± 15.64 years. The most common condition was rheumatoid arthritis (33.37%), followed by fibromyalgia (22.71%), Sjögren Syndrome (19.72%), and systemic lupus erythematosus (9.91%). Almost 7% of the patients presented polyautoimmunity. Thirty-five percent of the patients reported one or more ophthalmological symptoms, being dry eye sensation the most common (30.86%), followed by ocular pain (2.76%), red-eye, and decreased visual acuity (both 2.63%). Similarly, 21.45% of the patients presented one or more ophthalmological diagnoses, being keratoconjunctivitis sicca the most common (15.93%), followed by cataract, uveitis (1.38% each), and scleritis (1.25%).

          Conclusion

          Almost a third of the patients reported any ocular involvement. It is crucial to be aware of the most common ophthalmic manifestations among the different rheumatologic diseases in our population, to offer early specialist referral and timely treatment.

          Related collections

          Most cited references165

          • Record: found
          • Abstract: found
          • Article: not found

          Fibromyalgia: a clinical review.

          Fibromyalgia is present in as much as 2% to 8% of the population, is characterized by widespread pain, and is often accompanied by fatigue, memory problems, and sleep disturbances.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Myasthenia gravis

            Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane. Localized or general muscle weakness is the predominant symptom and is induced by the antibodies. Patients are grouped according to the presence of antibodies, symptoms, age at onset and thymus pathology. Diagnosis is straightforward in most patients with typical symptoms and a positive antibody test, although a detailed clinical and neurophysiological examination is important in antibody-negative patients. MG therapy should be ambitious and aim for clinical remission or only mild symptoms with near-normal function and quality of life. Treatment should be based on MG subgroup and includes symptomatic treatment using acetylcholinesterase inhibitors, thymectomy and immunotherapy. Intravenous immunoglobulin and plasma exchange are fast-acting treatments used for disease exacerbations, and intensive care is necessary during exacerbations with respiratory failure. Comorbidity is frequent, particularly in elderly patients. Active physical training should be encouraged.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Myasthenia gravis: subgroup classification and therapeutic strategies.

              Myasthenia gravis is an autoimmune disease that is characterised by muscle weakness and fatigue, is B-cell mediated, and is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. Patients with myasthenia gravis should be classified into subgroups to help with therapeutic decisions and prognosis. Subgroups based on serum antibodies and clinical features include early-onset, late-onset, thymoma, MUSK, LRP4, antibody-negative, and ocular forms of myasthenia gravis. Agrin-associated myasthenia gravis might emerge as a new entity. The prognosis is good with optimum symptomatic, immunosuppressive, and supportive treatment. Pyridostigmine is the preferred symptomatic treatment, and for patients who do not adequately respond to symptomatic therapy, corticosteroids, azathioprine, and thymectomy are first-line immunosuppressive treatments. Additional immunomodulatory drugs are emerging, but therapeutic decisions are hampered by the scarcity of controlled studies. Long-term drug treatment is essential for most patients and must be tailored to the particular form of myasthenia gravis.
                Bookmark

                Author and article information

                Journal
                Clin Ophthalmol
                Clin Ophthalmol
                opth
                clinop
                Clinical Ophthalmology (Auckland, N.Z.)
                Dove
                1177-5467
                1177-5483
                28 June 2021
                2021
                : 15
                : 2787-2802
                Affiliations
                [1 ]Neuroscience Research Group “NeURos”, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario , Bogotá, Colombia
                [2 ]Escuela Barraquer, Research Group, Escuela Superior de Oftalmología del Instituto Barraquer de América , Bogotá, Colombia
                [3 ]Fundación Para la Investigación en Dermatología y Reumatología (FUNINDERMA) , Bogotá, Colombia
                Author notes
                Correspondence: Alejandra de-la-Torre Neuroscience Research Group - NeURos, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario , Carrera 24 # 63C - 69, Bogotá, ColombiaTel +57 3102482196 Email alejadelatorre@yahoo.com
                Author information
                http://orcid.org/0000-0001-9088-5903
                http://orcid.org/0000-0002-9894-9323
                http://orcid.org/0000-0002-2326-7213
                http://orcid.org/0000-0003-1577-7894
                http://orcid.org/0000-0001-8781-5760
                http://orcid.org/0000-0003-0684-1989
                Article
                306621
                10.2147/OPTH.S306621
                8254180
                34234401
                92801079-6ebc-412e-90a6-52201d75a0d6
                © 2021 Uribe-Reina et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 14 February 2021
                : 20 April 2021
                Page count
                Figures: 1, Tables: 9, References: 166, Pages: 16
                Categories
                Original Research

                Ophthalmology & Optometry
                rheumatology,ophthalmology,ophthalmic findings,keratoconjunctivitis sicca,prevalence

                Comments

                Comment on this article